Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus GENCEPT 10 11 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus GENCEPT 10 11 21.
ENSKYCE vs GENCEPT 10/11-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
GENCEPT 10/11-21 is a combination contraceptive vaginal ring containing ethinyl estradiol and etonogestrel. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, inhibiting ovulation. Etonogestrel is a progestin that thickens cervical mucus, inhibiting sperm penetration, and alters the endometrium.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet (10 mg ethinyl estradiol and 11 mg gestodene on days 1-7, then placebo on days 8-21) orally once daily for 21 days, followed by 7 placebo days.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Terminal elimination half-life is 24-30 hours; allows once-daily dosing; steady-state achieved in 5-7 days
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal (30-40% as unchanged drug and metabolites), biliary/fecal (50-60% as metabolites)
Category C
Category C
Oral Contraceptive
Oral Contraceptive